Lease obligation, current 145,210 150,095
Accrued expenses and other
current liabilities 2,161,374 2,259,955
Insurance premium financing
payable 71,662 381,784
----------- -----------
Total current liabilities 4,907,466 3,438,601
Lease obligation, net of current
portion -- 90,124
-----------
Total liabilities 4,907,466 3,528,725
----------- -----------
Commitments and contingencies (see
Note 13)
Stockholders' equity:
Preferred stock, $0.001 par value;
10,000,000 shares authorized; 0
shares issued and outstanding at
September 30, 2024 and December 31,
2023 -- --
Common stock, $0.001 par value;
100,000,000 shares authorized;
7,464,070 and 6,186,280 shares
issued and outstanding at September
30, 2024 and December 31, 2023 7,464 6,186
Additional paid-in capital 81,748,225 77,871,584
Accumulated other comprehensive
(loss) income 1,754 877
Accumulated deficit (82,288,034) (66,900,725)
----------- -----------
Total stockholders' equity (530,591) 10,977,922
----------- -----------
Total liabilities and
stockholders' (deficit)
equity $ 4,376,875 $ 14,506,647
Inhibikase Therapeutics, Inc.
Condensed Consolidated Statements of Operations and
Comprehensive Loss
(Unaudited)
Three Months Ended Nine Months Ended September
September 30, 30,
-------------------------- ------------------------------
2024 2023 2024 2023
Revenue:
Grant revenue $ -- $ 79,569 $ -- $ 260,500
---------- ---------- ----------- -----------
Total revenue -- 79,569 -- 260,500
---------- ---------- ----------- -----------
Costs and
expenses:
Research and
development 4,189,873 3,225,551 10,016,982 10,615,368
Selling,
general and
administrative 1,637,603 1,622,894 5,643,386 5,331,358
---------- ---------- ----------- -----------
Total costs and
expenses 5,827,476 4,848,445 15,660,368 15,946,726
---------- ---------- ----------- -----------
Loss from
operations (5,827,476) (4,768,876) (15,660,368) (15,686,226)
Interest income
(expense) 49,410 173,677 273,059 835,283
---------- ---------- ----------- -----------
Net loss (5,778,066) (4,595,199) (15,387,309) (14,850,943)
Other
comprehensive
loss, net of tax
Unrealized
gains (loss)
on marketable
securities 2,778 1,571 877 (104,861)
---------- ---------- ----------- -----------
Comprehensive Loss $(5,775,288) $(4,593,628) $(15,386,432) $(14,955,804)
---------- ---------- ----------- -----------
Net loss per share
-- basic and
diluted $ (0.65) $ (0.75) $ (2.03) $ (2.48)
========== ========== =========== ===========
Weighted-average
number of common
shares -- basic
and diluted 8,882,570 6,162,671 7,592,103 5,977,841
========== ========== =========== ===========
(END) Dow Jones Newswires
November 14, 2024 08:37 ET (13:37 GMT)